Hormone abuse in adolescents and adults: A review of current knowledge

Endocrinologist

Volumn 15, Issue 2, 2005, Pages 115-125

  Dickinson, Barry ^a   Goldberg, Linn ^b   Elliot, Diane ^b   Spratt, Daniel ^c,d   Rogol, Alan D ^e,f,i   Fish, Lisa H ^g,h,j  

^a AMERICAN MEDICAL ASSOCIATION   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d MMC Research Institute   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h Hormone Foundation   (United States)

ⁱ Solvay Pharmaceuticals Inc   (Belgium)

^j PARK NICOLLET CLINIC   (United States)

more..

Author keywords

Adolescent; Anabolic steroid; Athlete; Hormone abuse

Indexed keywords

4 ANDROSTENEDIOL; ANABOLIC AGENT; ANDROGEN; ANDROSTENEDIOL; ANDROSTENEDIONE; ERYTHROPOIETIN; ESTR 4 ENE 3,17 DIONE; ESTROGEN; GROWTH HORMONE; MESTEROLONE; METHYLTESTOSTERONE; NANDROLONE; NON PRESCRIPTION DRUG; PRASTERONE; SOMATOMEDIN; TESTOSTERONE; TESTOSTERONE ENANTATE;

ACADEMIC ACHIEVEMENT; ACNE; ALOPECIA; ATHLETE; CARDIOVASCULAR DISEASE; DOPING; DRUG SCREENING; EDUCATION PROGRAM; EMOTIONAL DISORDER; GROWTH DISORDER; GYNECOMASTIA; HIRSUTISM; HUMAN; HYPOGONADISM; LIVER TOXICITY; MUSCLE ATROPHY; MUSCLE STRENGTH; PHYSICAL PERFORMANCE; PREVALENCE; REVIEW; SUBSTANCE ABUSE; VIRILIZATION;

EID: 15244360707     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000157881.51030.b4     Document Type: Review

References (131)

1. Yesalis CE, ed. Anabolic Steroids in Sport and Exercise, 2nd ed. Champaign, IL: Human Kinetics; 2000.
2. Buckley WE, Yesalis CE, Friedl KE, et al. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA. 1988;260:3441-3445.
3. Scott DM, Wagner JC, Barlow TW. Anabolic steroid use among adolescents in Nebraska schools. Am J Health Syst Pharm. 1996;53:2068-2072.
4. Stilger VG, Yesalis CE. Anabolic-androgenic steroid use among high school football players. J Community Health. 1999;24:131-145.
5. Tanner SM, Miller DW, Alongi C. Anabolic steroid use by adolescents: prevalence, motives, and knowledge of risks. Clin J Sport Med. 1995;5:108-115.
6. Whitehead R, Chillag S, Elliot D. Anabolic steroid use among adolescents in a rural state. J Fam Pract. 1992;35:401-405.
7. Irving LM, Wall M, Neumark-Sztainer D, et al. Steroid use among adolescents: findings from Project EAT. J Adolesc Health. 2002;30:243-252.
8. Johnston LD, O'Malley PM, Bachman JG. Demographic subgroup trends for various licit and illicit drugs, 1975-2001. Monitoring the Future, Occasional paper No. 57. Ann Arbor, MI: Institute for Social Research. Available at: http://monitoringthefuture.org/pubs/occpapers/occ57.pdf. Accessed February 24, 2003.
9. NIDA InfoFacts. Teen Drug Abuse - High School and Youth Trends. National Institute on Drug Abuse. Available at: http://www.drugabuse.gov/Infofax/ HSYouthtrends.htm. Accessed February 22, 2003.
10. National Center for Chronic Disease Prevention and Health Promotion. Youth Risk Behavior Surveillance System. Youth 2001 Online. Available at: http://www.cdc.gov/nccdphp/dash/yrbs/2001/youth01online.htm. Accessed February 21, 2003.
11. National Household Survey on Drug Abuse. United States Department of health and Human Services. Available at: http://www.samhsa.gov/oas/nhsda. htm#NHSDAinfo. Accessed February 20, 2003.
12. Yesalis CE, Bahrke MS. Anabolic-androgenic steroids: current issues. Sports Med. 1995;19:326-340.
13. Nutter J. Middle school students' attitudes and use of anabolic steroids. J Strength Cond Res. 1997;11:35-39.
14. Kreipe RE, Golden NH, Katzman DK, et al. Eating disorders in adolescents: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 1995;16:476-479.
15. Anderson SW, Albrech RR, McKeag DB. A national survey of alcohol and drug use by college athletes. Phys Sports Med. 1991;19:91-104.
16. Kersey RD. Anabolic-androgenic steroid use by private health club/gym athletes. J Strength Cond Res. 1993;7:118-126.
17. Elliot D, Moe E, Duncan T, et al. Who are the young women at risk for anabolic steroid use? Med Sci Sports Exerc. 1999;31:S123.
18. Gruber AJ, Pope HG. Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom. 2000;69:19-26.
19. Taub DE, Blinde EM. Eating disorders among adolescent female athletes: influence of athletic participation and sport team membership. Adolescence. 1992;27:833-848.
20. Moe EL, Goldberg L, MacKinnon D, et al. Nutritional supplements: are they precursors to anabolic steroid and other substance use? [Abstract]. Presented at the 2002 meeting of the Society for Prevention Research, Seattle, WA.
21. Elliot D, Goldberg L. Intervention and prevention of steroid use in adolescents. Am J Sports Med. 1996;24:S-46-47.
22. Elliot D, Moe E, Duncan T, et al. Who are the young women at risk for anabolic steroid use? Med Sci Sports Exerc. 1999;31:S123.
23. Yesalis CE, Kennedy NK, Kopstein AN, et al. Anabolic-androgenic steroid use in the United States. JAMA. 1993;270:1217-1221.
24. DuRant RH, Escobedo LG, Heath GW. Anabolic-steroid use, strength training, and multiple drug use among adolescents in the United States. Pediatrics. 1995;96:23-28.
25. DuRant RH, Rickert VI, Ashworth C, et al. Use of multiple drugs among adolescents who use anabolic steroids. N Engl J Med. 1993;328:922-926.
26. Aaron DJ, Dearwater SR, Anderson R, et al. Physical activity and the initiation of high-risk health behaviors in adolescents. Med Sci Sports Exerc. 1995;27:1639-1642.
27. Kokotailo PK, Henry BC, Koscik RE, et al. Substance use and other health risk behaviors in collegiate athletes. Clin J Sports Med. 1996;6:183-189.
28. Leder BZ, Longcope C, Catlin DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA. 2000;283:779-782.
29. Brown WJ, Basil MD, Bocarnea MC. The influence of famous athletes on health beliefs and practices: Mark McGwire, child abuse prevention, and androstenedione. J Health Commun. 2003;8:41-57.
30. Rickert VI, Pawlak-Morello C, Sheppard V, et al. Human growth hormone: a new substance of abuse among adolescents? Clin Pediatr. 1992;31:723-726.
31. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:55-69.
32. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med. 1984;12:469-84.
33. Ryan AJ. Anabolic steroids are fool's gold. Fed Proc. 1981;40:2682-2688.
34. Wilson JD. Androgen abuse by athletes. Endocr Rev. 1988;9:181-199.
35. Elashoff JD, Jacknow AD, Shain SG, et al. Effects of androgenic-anabolic steroid on muscle strength. Ann Intern Med. 1991;15:387-393.
36. Crist DM, Stackpole PJ, Peake GT. Effects of androgenic-anabolic steroids on neuromuscular power and body composition. J Appl Physiol. 1983;54:366-370.
37. King DS, Sharp RL, Vukovich MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA. 1999;281:2020-2028.
38. Ariel G, Saville W. Effect of anabolic steroids on reflex components. J Appl Physiol. 1972;32:795-797.
39. Freed DL, Banks AJ, Longson D, et al. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. BMJ. 1975;2:471-473.
40. Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes. A case series analysis. Am J Sports Med. 1990;18:422-428.
41. Hervey GR, Knibbs AV, Burkinshaw L, et al. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin Sci (Lond). 1981;60:457-461.
42. Sheffield-Moore M, Urban RJ, Wolf SE. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab. 1999;84:2705-2711.
43. Bhasin S, Storer TW, Berman N. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335:1-7.
44. Giorgi A, Weatherby RP, Murphy PW. Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study. J Sci Med Sport. 1999;2:341-355.
45. Knuth UA, Maniera H, Nieschlag E. Anabolic steroids and semen parameters in bodybuilders. Fertil Steril. 1989;52:1041-1047.
46. Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med. 1990;18:429-431.
47. Torres-Calleja J, De Celis R, Gonzalez-Unzaga M, et al. Effect of androgenic anabolic steroids on semen parameters and hormone levels in bodybuilders. Fertil Steril. 2000;74:1055-1056.
48. Malarkey WB, Strauss RH, Leizman DJ, et al. Endocrine effects in female weight lifters who self-administer testosterone and anabolic steroids. Am J Obstet Gynecol. 1991;165:1385-1390.
49. Turek PJ, Williams RH, Gilbaugh JH, et al. The reversibility of anabolic steroid-induced azoospermia. J Urol. 1995;153:1628-1630.
50. Gazvani MR, Buckett W, Luckas MJ, et al. Conservative management of azoospermia following steroid abuse. Hum Reprod. 1997;12:1706-1708.
51. Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weight-trained women athletes. JAMA. 1985;253:2871-2873.
52. Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med. 1997;18:557-562.
53. Aiache AE. Surgical treatment of gynecomastia in the body builder. Plast Reconstr Surg. 1989;83:61-66.
54. Babigian A, Silverman RT. Management of gynecomastia due to use of anabolic steroids in bodybuilders. Plast Reconstr Surg. 2001;107:240-242.
55. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis. 1987;7:230-236.
56. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a review for the clinician. Sports Med. 2002;32:285-296.
57. Yoshida EM, Erb SR, Scudamore CH, et al. Severe cholestasis and jaundice secondary to an esterified testosterone, a non-C17 alkylated anabolic steroid. J Clin Gastroenterol. 1994;18:268-270.
58. Zevin D, Turani H, Cohen A, et al. Androgen-associated hepatoma in a hemodialysis patient. Nephron. 1981;29:274-276.
59. Overly WL, Dankoff JA, Wang BK, et al. Androgens and hepatocellular carcinoma in an athlete. Ann Intern Med. 1984;100:158-159.
60. Nakao A, Sakagami K, Nakata Y, et al. Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J Gastroenterol. 2000;35:557-562.
61. de Menis EP, Tramontin, Conte N. Danazol and multiple hepatic adenomas: peculiar clinical findings in an acromegalic patient. Horm Metab Res. 1999;31:476-477.
62. Friedl K. Reappraisal of the health risks associated with the use of high doses of oral and injectable androgenic steroids. NIDA Res Monogr. 1990;102:142-177.
63. Bagberi S. Peliosis hepatis associated with anabolic-androgenic steroid therapy: a severe form of hepatic injury. Ann Intern Med. 1974;81:610-618.
64. Turani H, Levi J, Zevin D, et al. Hepatic lesions in patients on anabolic androgenic therapy. Isr J Med Sci. 1983;19:332-337.
65. Wakabayashi T, Onda H, Tada T, et al. High incidence of peliosis hepatis in autopsy cases of aplastic anemia with special reference to anabolic steroid therapy. Acta Pathol Jpn. 1984;34:1079-1086.
66. Hurley BF, Seals DR, Hagberg JM. High-density-lipoprotein cholesterol in bodybuilders v powerlifters: negative effects of androgen use. JAMA. 1984;252:507-513.
67. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels: a literature review. Arch Intern Med. 1991;151:1925-1933.
68. McNutt RA, Ferenchick GS, Kirlin PC, et al. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol. 1988;62:164.
69. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust. 1993;158:346-348.
70. Fisher M, Appleby M, Rittoo D, et al. Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract. 1996;50:222-223.
71. Drinka PJ, Jochen AL, Cuisinier M, et al. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc. 1995;43:899-901.
72. Sullivan ML, Martinez CM, Gennis P, et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41:1-15.
73. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiatry. 1994;51:375-382.
74. Tricker R, Casaburi R, Storer TW, et al. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men - a clinical research center study. J Clin Endocrinol Metab. 1996;81:3754-3758.
75. Bahrke MS, Wright JE, Strauss RH, et al. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. Am J Sports Med. 1992;20:717-724.
76. Ziegenfuss TN, Berardi JM, Lowery LM. Effects of prohormone supplementation in humans: a review. Can J Appl Physiol. 2002;27:628-646.
77. Leder BZ, Longcope C, Catlin DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA. 2000;283:779-782.
78. Brown GA, Vukovich MD, Reifenrath TA, et al. Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men. Int J Sport Nutr Exerc Metab. 2000;10:340-359.
79. Rasmussen BB, Volpi E, Gore DC, et al. Androstenedione does not stimulate muscle protein anabolism in young healthy men. J Clin Endocrinol Metab. 2000;85:55-59.
80. Wallace MB, Lim J, Cutler A, et al. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc. 1999;31:1788-1792.
81. Ballantyne CS, Phillips SM, MacDonald JR, et al. The acute effects of androstenedione supplementation in healthy young males. Can J Appl Physiol. 2000;25:68-78.
82. Broeder CE, Quindry J, Brittingham K, et al. The Andro Project: physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med. 2000;160:3093-3104.
83. Brown GA, Martini ER, Roberts BS, et al. Acute hormonal response to sublingual androstenediol intake in young men. J Appl Physiol. 2002;92:142-146.
84. Brown GA, Vukovich MD, Martini ER, et al. Endocrine and lipid responses to chronic androstenediol-herbal supplementation in 30 to 58 year old men. J Am Coll Nutr. 2001;20:520-528.
85. Colker CM, Antonio J, Kalman D. The metabolism of orally ingested 19-nor-4-androstene-3,17-dione and 19-nor-4-androstene-3,17-diol in healthy, resistance-trained men. J Strength Cond Res. 2001;15:144-147.
86. van Gammeren D, Falk D, Antonio J. Effects of norandrostenedione and norandrostenediol in resistance-trained men. Nutrition. 2002;18:734-737.
87. Kicman AT, Bassindale T, Cowan DA, et al. Effect of androstenedione ingestion on plasma testosterone in young women; a dietary supplement with potential health risks. Clin Chem. 2003;49:167-169.
88. Parasrampuria JK, Schwartz, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA. 1998;280:1565.
89. Catlin DH, et al. Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite. JAMA. 2000;284:2618-2621.
90. Geyer H. Analysis of 'non-hormonal' nutritional supplements for prohormones. In: Schanzer W, Gotzmann A, Geyer H, et al., eds. Proceedings of the 19th Koln Workshop on Dope Analysis; Institut fur Biochemie, Koln, Germany; March 2001.
91. Green GA, Catlin DH, Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med. 2001;11:254-259.
92. Ehrnborg C, Bengtsson BA, Rosen T. Growth hormone abuse. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:71-77.
93. Jenkins PJ. Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res. 2001;11(suppl A):S71-S77.
94. Rickert VI, Pawlak-Morello C, Sheppard V, et al. Human growth hormone: a new substance of abuse among adolescents? Clin Pediatr. 1992;31:723-726.
95. Spivak JL. Erythropoietin use and abuse: when physiology and pharmacology collide. Adv Exp Med Biol. 2001;502:207-224.
96. Jelkmann W, Hellwig-Burgel T. Biology of erythropoietin. Adv Exp Med Biol. 2001;502:169-187.
97. Ibbotson T, Goa KL. Darbepoetin alfa. Drugs. 2001;61:2097-2104.
98. Audran M, Gareau R, Matecki S, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc. 1999;31:639-645.
99. Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med. 1991;229:125-130.
100. Birkeland KI, Stray-Gundersen J, Hemmersbach P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc. 2001;32:1238-1243.
101. Russell G, Gore CJ, Ashenden MJ, et al. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol. 2002;86:548.
102. Clark PA, Rogol AD. Somatic growth and its regulation. In: Kostyo JL, ed. Hormonal Control of Growth, vol. 5. Section on endocrinology. In: Goodman HM, ed, section 7. Handbook of Physiology. New York: Oxford Press; 1999:37-72.
103. Mauras N, Haymond MW. Metabolic effects of recombinant human insulin-like growth factor I in humans: comparison with recombinant human growth hormone. Pediatr Nephrol. 1996;10:318-323.
104. Fuentes RJ, Rosenberg JM, David A. Athletic Drug Reference 1995. RTP, North Carolina: Clean Data, Inc; 1995.
105. Husch J, ed. Programme on Substance Abuse: Drug Use and Sport; Current Issues and Implications for Public Health. Geneva: World Health Organization; 1993.
106. Normand J, Lempert RO, O'Brien PO, eds. Under the Influence? Drugs and the American Work Force. Committee on Drug Use in the Workplace, National Research Council/Institute of Medicine. ISBN 0-309-04885-0. Washington, DC: National Academy Press; 1994.
107. Zwerling C. Drug testing. JAMA. 1994;272:1467-1468.
108. Yamaguchi R, Johnston LD, O'Malley PM. Relationship between student illicit drug use and school drug-testing policies. J Sch Health. 2003;73:159-164.
109. http://www.nfhs.org/scriptcontent/va_Custom/va_cm/contentpagedisplay.cfm? content_id=236.
110. Catlin DH, Murray TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA. 1996;276:231-237.
111. Ayotte C, Goudreault D, Charlebois A. testing for natural and synthetic anabolic agents in human urine. J Chromatography. 1996;687:3-25.
112. Saugy M, Cardis C, Robinson N, et al. Test methods: anabolics. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:111-133.
113. Videman T, Lereim I, Hemmingsson P, et al. Changes in hemoglobin values in elite cross-country skiers from 1987-1999. Scand J Med Sci Sports. 2000;10:98-102.
114. Kazlauskas R, Howe C, Trout G. Strategies for rhEPO detection in sport. Clin J Sport Med. 2002;12:229-235.
115. Wilber RL. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med. 2002;32:125-142.
116. Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:99-109.
117. Kniess A, Ziegler E, Kratzsch J, et al. Potential parameters for the detection of hGH doping. Anal Bioanal Chem. 2003;376:696-700.
118. GH-2000 Consortium. Available at: www.umds.ac.uk/medicine/endocrinology/ projects/gh-2000.htm. Accessed January 22, 2003.
119. Coombs RH, Ryan FJ. Drug testing effectiveness in identifying and preventing drug use. Am J Drug Alcohol Abuse. 1990;16:173-184.
120. Albrecht RR, Anderson WA, McKeag DB. Drug testing of college athletes: the issues. Sports Med. 1992;14:349-352.
121. Steroid use drops among student athletes. NCAA News. September 1, 1993:1.
122. Only 0.3% ruled ineligible in fall 1993 drug testing. NCAA News. June 4, 1994:1.
123. Goldberg L, Elliot D, MacKinnon D, et al. Drug testing athletes to prevent substance abuse: background and pilot study results of the SATURN (Student Athlete Testing Using Random Notification) study. J Adolesc Health. 2003;32:16-25.
124. Dupont RL, Griffith DW, Siskin BR, et al. Random drug tests at work: the probability of identifying frequent and infrequent users of illicit drugs. J Addict Dis. 1995;14:1-17.
125. National Institute on Drug Abuse. Preventing Drug Use Among Children and Adolescents: A Research-Based Guide. US Department of Health and Human Services; National Institutes of Health; National Institute on Drug Abuse. NIH Publication No 97-4212, 1997.
126. Goldberg L, Bents R, Bosworth E, et al. Anabolic steroid education and adolescents: do scare tactics work? Pediatrics. 1991;87:283-286.
127. Goldberg L, Elliot DL, Bosworth E, et al. Boomerang effects of drug education programs. Pediatrics. 1991;88:1079.
128. Moe EL, Elliot DL, Duncan TE, et al. Disordered eating and drug use: defining a model and identifying components for a prevention curriculum. J Invest Med. 2002;50.
129. Elliot D, Goldberg L, Moe E, et al. ATHENA. Deterring drug use and disordered eating. J Invest Med. 2002;50.
130. Goldberg L, Elliot D, MacKinnon DP, et al. Effects of a multi-dimensional steroid prevention intervention: the ATLAS (Adolescents Training and Learning to Avoid Steroids) Program. JAMA. 1996;276:1555-1562.
131. Goldberg L, MacKinnon DP, Elliot DL, et al. The Adolescents Training and Learning to Avoid Steroids Program preventing drug use and promoting health behaviors. Arch Pediatr Adolesc Med. 2000;154:332-3H.